The U.S. government signed a $354 million four-year contract with new pharmaceutical company Phlow Corp. to increase American production of medications that may help treat Covid-19 in a bid to avoid potential supply chain shortages, with the potential to extend the contract to $812 million for the next ten years.
A new Richmond-based pharmaceutical manufacturing company has received a $354 million federal contract to help build a strategic, national reserve of essential medications and to make active ingredients for more than a dozen medicines used to treat patients with COVID-19.
Health security is critical to national security. The Covid-19 pandemic is a moment to re-evaluate U.S. dependence on China for pharmaceutical ingredients and to solidify the pharmaceutical supply chain.
Countries around the world are scrambling to source more ventilators for patients infected with coronavirus, but doctors fear that these will be useless without essential drugs to keep patients comfortable, the Bureau of Investigative Journalism can reveal.
The Bureau of Investigative Journalism | April 9, 2020